SA4Ag vaccine low dose + SA4Ag vaccine mid dose + SA4Ag vaccine high dose + Placebo

Phase 1Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Staphylococcal Infections

Conditions

Staphylococcal Infections

Trial Timeline

Aug 1, 2011 → Jan 1, 2013

NCT ID

NCT01364571

About SA4Ag vaccine low dose + SA4Ag vaccine mid dose + SA4Ag vaccine high dose + Placebo

SA4Ag vaccine low dose + SA4Ag vaccine mid dose + SA4Ag vaccine high dose + Placebo is a phase 1 stage product being developed by Pfizer for Staphylococcal Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT01364571. Target conditions include Staphylococcal Infections.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01364571	Phase 1	Completed	Aug 1, 2011	Jan 1, 2013	Staphylococcal Infections

Competing Products

20 competing products in Staphylococcal Infections

See all competitors

Product	Company	Stage	Hype Score
Ceftobiprole	Johnson & Johnson	Phase 1	33
Ceftobiprole	Johnson & Johnson	Phase 1	33
Daptomycin + Vancomycin	Merck	Approved	85
Daptomycin 4 mg/kg + Comparator: vancomycin + Daptomycin 6 mg/kg	Merck	Phase 3	77
V710 + Placebo	Merck	Phase 1	33
V710 + Comparator: Placebo	Merck	Phase 1	33
V710 (30 µg) with MAA + V710 (30 µg) without MAA	Merck	Phase 1	33
Daptomycin + Vancomycin	Merck	Approved	85
Daptomycin	Novartis	Approved	85
SA4Ag vaccine	Pfizer	Phase 1	32
Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine	Pfizer	Phase 2	51
linezolid (Zyvox)	Pfizer	Pre-clinical	22
Staphylococcus aureus 4-antigen vaccine + Placebo	Pfizer	Phase 2	51
Tigecycline	Pfizer	Approved	84
SA4Ag vaccine low dose + SA4Ag vaccine mid dose + SA4Ag vaccine high dose + SA3Ag vaccine + Placebo	Pfizer	Phase 1	32
NDV-3 vaccine with alum IM + NDV-3 vaccine without alum IM + Placebo with alum IM + NDV-3 vaccine without alum ID	United Therapeutics	Phase 1	30
NDV-3 investigational vaccine	United Therapeutics	Phase 1	30
TD-1792 + Vancomycin	Theravance Biopharma	Phase 2	47
Ceftobiprole	Basilea Pharmaceutica	Phase 1	28
human lactoferrin peptide 1-11	AM-Pharma	Phase 1/2	33

Other Products from Pfizer